ClinicalTrials.gg
Not yet recruitingNCT07329205RCTUpdated Jan 9, 2026

Femoral Nerve Mobilization for Patients With Knee Osteoarthritis

An interventional study of traditional physical therapy and Femoral nerve mobilization in Knee Osteoarthristis, sponsored by Prince Sattam Bin Abdulaziz University. Not yet recruiting at 1 site in Saudi Arabia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Prince Sattam Bin Abdulaziz University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Background: Knee osteoarthritis (KO) is considered as a cause of disability among the elderly, causing pain, reduced quality of life, and decreased functionality. There is a limited knowledge about using femoral nerve mobilization in treating patients with arthritic changes.

Objectives: This study will be designed to determine the efficacy of adding of femoral nerve mobilization on pain intensity, function, quality of life and central sensitization in patients with knee osteoarthritis Methods: Thirty patients (aged ≥50 years with KO Kellgren-Lawrence grades I-II) will be included in this study: Patients will randomly be assigned into two groups: group A will receive traditional physical therapy while group B will receive femoral nerve mobilization in addition to traditional physical therapy. Three sessions will be performed for four weeks by 3 session /week. Patients will be evaluated for pain intensity using the numerical rating scale (NRS), knee function by WOMAC scale, quality of life by 12-item Short Form Survey questionnaire (SF-12) and central sensitization by the Arabic version of central sensitization inventory (CSI).

02

Conditions studied

  • Knee Osteoarthristis

Keywords

  • NEURAL MOBILIZATION
  • Knee osteoarthritis
  • conventional physical therapy
03

In context

Osteoarthritis, Knee

3,292 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 50 is below the median of 68 across 2,714 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Prince Sattam Bin Abdulaziz University is the lead sponsor of 35 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 50 years or older, diagnosed with KO according to theAmerican College of Rheumatology's criteria with knee pain, and grade I or II on the Kellgren-Lawrence radiographic scale

Exclusion criteria

Exclusion Criteria:

  • individuals suffering from chronic conditions considered to be perpetuating factors (e.g., fibromyalgia)
  • those with conditions causing lower extremity pain
  • individuals who had taken analgesics within 24 h before evaluations
  • those who had undergone or local anesthetic infiltration in the year prior to the study or during the follow-up period
  • those using substances that could interfere with treatment
  • those with a previous diagnosis of neuropathy (lumbosacral plexus) or myopathy
  • those with to mobilization or exercise, and those with cognitive deficits (dementia, Alzheimer's).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Control group

    Traditional physical therapy

    Other: traditional physical therapy

  • Experimental
    Neural mobilization group

    traditional physical therapy plus femoral nerve mobilization

    Other: traditional physical therapy · Other: Femoral nerve mobilization

Interventions

  • Othertraditional physical therapy

    stretching exercises for hamstring, calf muscles and iliotibial band in addition to isotonic exercise for hip extensors and abductors and isometric quadriceps exercise

  • OtherFemoral nerve mobilization

    A physiotherapist guided the patients in performing active mobilization of the femoral nerve. The prescribed method for active neural mobilization involved assuming a prone position supported by the forearms with a slight extension of the spine, flexion of the knee, and extension of the cervical spine. This was followed by performing the opposite movement

06

What researchers measure

Primary outcomes

  1. pain intensity

    The pain was assessed by the numerical rating scale (NRS) where zero indicating no pain and 10 indicating maximal pain

    Time frame: after 4 weeks

  2. central sensitization

    The CSI is a validated questionnaire designed to identify symptoms associated with central sensitization. It has two components: Scale A assesses 25 common symptoms in individuals with central sensitization, resulting in a score ranging from 0 to 100. This score was interpreted as follows: subclinical (0-29), mild (30-39), moderate (40-49), severe (50-59), and extreme (60-100). Scale B, which is not scored, collects information on previous diagnoses of specific diseases

    Time frame: after 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Pedersini P, Valdes K, Cantero-Tellez R, Cleland JA, Bishop MD, Villafane JH. Effects of Neurodynamic Mobilizations on Pain Hypersensitivity in Patients With Hand Osteoarthritis Compared to Robotic Assisted Mobilization: A Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2021 Feb;73(2):232-239. doi: 10.1002/acr.24103. Epub 2021 Jan 3. PubMed 31675184 ↗
  • Serrano-Garcia B, Martinez-Cepa CB, Forriol F, Zuil-Escobar JC. Active Neurodynamic Technique at Home in Patients with Knee Osteoarthritis: An Open Single Arm Clinical Trial. Medicina (Kaunas). 2024 Nov 12;60(11):1857. doi: 10.3390/medicina60111857. PubMed 39597042 ↗
  • Serrano-Garcia B, Forriol-Campos F, Zuil-Escobar JC. Active Neurodynamics at Home in Patients with Knee Osteoarthritis: A Feasibility Study. J Clin Med. 2023 Oct 20;12(20):6635. doi: 10.3390/jcm12206635. PubMed 37892772 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Feb 2026, 1 month later.

Of 1,111 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 1 month is below that.

Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 9, 2026
StartEst.
Dec 20, 2025
Primary completionEst.
Feb 10, 2026
CompletionEst.
Feb 25, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329205
Lead sponsor
Prince Sattam Bin Abdulaziz University
Responsible party
Mohammad Moustafa Aldosoukki Hegazy (assisstant professor , department of health and rehabilitation sciences, college of applied medical siences, Prince Sattam Bin Abdulaziz University) — Principal investigator
First posted
Jan 9, 2026
Start date
Dec 20, 2025 (estimated)
Primary completion
Feb 10, 2026 (estimated)
Completion
Feb 25, 2026 (estimated)
Last update
Jan 9, 2026

Study contacts

Mohammed Hegazy, Phd
Contact
mohamed.mostafa@pt.cu.edu.eg
00966566169893 ext. 00966115886387

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion